CTRI/2019/10/021712已完成2 期
A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Individualized Homeopathic Medicines in Atopic Dermatitis in Adults
Mahesh Bhattacharyya Homoeopathic Medical College Hospital Govt of West Bengal0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Newly diagnosed cases of AD (ICD-10-CM code L20.9) as per UK diagnostic criteria
- •2. PO-SCORAD more than 10
- •3. Age: 18-65 years
- •4. Both sexes
- •5. Literate patients; ability to read Bengali
- •6. Patients giving written consent to participate
- •7. Patients already undergoing treatment for AD were planned to be recruited on completely stopping the medicines and after wash-out phase of 1 month
排除标准
- •1. Patients who were too sick for consultation
- •2. Diagnosed cases of unstable psychiatric or uncontrolled or life-threatening systemic illness affecting QoL or any organ failure
- •3. Substance abuse and/or dependence
- •4. Pregnant and lactating women
- •5. Patients undergoing homeopathic treatment for any chronic disease within last 6 months
研究者
相似试验
进行中（未招募）
1 期
A trial for children and teenagers with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) to determine how effective Ganaxolone treatment is.EUCTR2018-001180-23-FRMarinus Pharmaceuticals, Inc.70
进行中（未招募）
1 期
A trial for children and teenagers with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) to determine how effective Ganaxolone treatment is.EUCTR2018-001180-23-GBMarinus Pharmaceuticals, Inc.100
进行中（未招募）
1 期
A trial for children and teenagers with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) to determine how effective Ganaxolone treatment is.EUCTR2018-001180-23-ITMarinus Pharmaceuticals, Inc.70
招募中
2 期
Homeopathic medicines for problems related to incomplete and unsatisfactory bowel movementCTRI/2019/10/021632Mahesh Bhattacharyya Homoeopathic Medical College Hospital Govt of West Bengal
进行中（未招募）
1 期
A trial for children and teenagers with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) to determine how effective Ganaxolone treatment is.EUCTR2018-001180-23-PLMarinus Pharmaceuticals, Inc.100